

7. REFERENCES

- Alipour M., Khoobi M., Moradi A., Nadri H., Moghadam F.H., Emami S., Hasanpour Z., Foroumadi A. and Shafiee A., "Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives," *European Journal of Medicinal Chemistry*, **82**(2014)536-544.
- Alves M.A., de Queiroz A.C., Alexandre-Moreira M.S., Varela J., Cerecetto H., González M., Dorigueto A.C., Landre I.M., Barreiro E.J. and Lima L.M., "Design, synthesis and in vitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives," *European Journal of Medicinal Chemistry*, **100**(2015)24-33.
- Avila J., Lucas J.J., Perez M. and Hernandez F., "Role of tau protein in both physiological and pathological conditions," *Physiological Reviews*, (2), **84**(2004)361-384.
- Beal, M.F., Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*, 1992. **31**(2): p. 119-130.
- Bagheri M., Joghataei M.-T., Mohseni S. and Roghani M., "Genistein ameliorates learning and memory deficits in amyloid β (1–40) rat model of Alzheimer's disease," *Neurobiology of Learning and Memory*, (3), **95**(2011)270-276.
- Bencheikroun M., Bartolini M., Egea J., Romero A., Soriano E., Pudlo M., Luzet V., Andrisano V., Jimeno M.L. and López M.G., "Novel Tacrine-Grafted Ugi Adducts as Multipotent Anti-Alzheimer Drugs: A Synthetic Renewal in Tacrine–Ferulic Acid Hybrids," *ChemMedChem*, (3), **10**(2015a)523-539.
- Bencheikroun M., Ismaili L., Pudlo M., Luzet V., Gharbi T., Refouvelet B. and Marco-Contelles J., "Donepezil–ferulic acid hybrids as anti-Alzheimer drugs," *Future Medicinal Chemistry*, (1), **7**(2015b)15-21.
- Bencheikroun M., Romero A., Egea J., Leon R., Michalska P., Buendia I., Jimeno M.L., Jun D., Janockova J. and Sepsova V., "The antioxidant additive approach for Alzheimer's disease therapy: new ferulic (lipoic) acid plus melatonin modified tacrines as cholinesterases inhibitors, direct antioxidants, and nuclear factor (erythroid-derived 2)-like 2 activators," *Journal of Medicinal Chemistry*, (21), **59**(2016)9967-9973.
- Beninger R.J., Wirsching B., Jhamandas K. and Boegman R., "Animal studies of brain acetylcholine and memory," *Archives of Gerontology and Geriatrics*, 1989).
- Bitner R.S., "Cyclic AMP response element-binding protein (CREB) phosphorylation: a mechanistic marker in the development of memory enhancing Alzheimer's disease therapeutics," *Biochemical Pharmacology*, (6), **83**(2012)705-714.
- Bolognesi M.L., Cavalli A., Valgimigli L., Bartolini M., Rosini M., Andrisano V., Recanatini M. and Melchiorre C., "Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease," *Journal of Medicinal Chemistry*, (26), **50**(2007)6446-6449.

- Bonda D.J., Wang X., Perry G., Nunomura A., Tabaton M., Zhu X. and Smith M.A., "Oxidative stress in Alzheimer disease: a possibility for prevention," *Neuropharmacology*, (4-5),**59**(2010)290-294.
- Borroni B., Benussi A., Premi E., Alberici A., Marcello E., Gardoni F., Di Luca M. and Padovani A., "Biological, neuroimaging, and neurophysiological markers in frontotemporal dementia: three faces of the same coin," *Journal of Alzheimer's Disease*, (3),**62**(2018)1113-1123.
- Braak H. and Braak E., "Frequency of stages of Alzheimer-related lesions in different age categories," *Neurobiology of Aging*, (4),**18**(1997)351-357.
- Bradford M.M., "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding," *Analytical Biochemistry*, (1-2),**72**(1976)248-254.
- Bunnett J.F. and Zahler R.E., "Aromatic Nucleophilic Substitution Reactions," *Chemical Reviews*, (2),**49**(1951)273-412.
- Burger A. (1991) *Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques*, pp. 287-371, Springer.
- Colaïanna M., Tucci P., Zotti M., Morgese M.G., Schiavone S., Govoni S., Cuomo V. and Trabace L., "Soluble β amyloid1-42: a critical player in producing behavioural and biochemical changes evoking depressive-related state?," *British Journal of Pharmacology*, (8),**159**(2010)1704-1715.
- Di L., Kerns E.H., Fan K., McConnell O.J. and Carter G.T., "High throughput artificial membrane permeability assay for blood-brain barrier," *European Journal of Medicinal Chemistry*, (3),**38**(2003)223-232.
- Dibner C., Schibler U. and Albrecht U., "The mammalian circadian timing system: organization and coordination of central and peripheral clocks," *Annual Review of Physiology*, **72**(2010)517-549.
- Dixon M., "The graphical determination of K_m and K_i ," *Biochemical Journal*, (1),**129**(1972)197-202.
- Egan M.F., Kost J., Tariot P.N., Aisen P.S., Cummings J.L., Vellas B., Sur C., Mukai Y., Voss T. and Furtek C., "Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease," *New England Journal of Medicine*, (18),**378**(2018)1691-1703.
- Ellman G.L., Courtney K.D., Andres Jr V. and Featherstone R.M., "A new and rapid colorimetric determination of acetylcholinesterase activity," *Biochemical Pharmacology*, (2),**7**(1961)88-95.
- Enciu A.M., Nicolescu M.I., Manole C.G., Mureșanu D.F., Popescu L.M. and Popescu B.O., "Neuroregeneration in neurodegenerative disorders," *BMC Neurology*, (1),**11**(2011)75.
- Fang L., Kraus B., Lehmann J., Heilmann J., Zhang Y. and Decker M., "Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates," *Bioorganic & Medicinal Chemistry Letters*, (9),**18**(2008)2905-2909.

- Forman M., Kleijn H.-J., Dockendorf M., Palcza J., Tseng J., Canales C., Egan M., Kennedy M., Laterza O. and Ma L., "The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease," *Alzheimer's & dementia: the journal of the Alzheimer's Association*, (4),**9**(2013)P139.
- Galpern W.R. and Lang A.E., "Interface between tauopathies and synucleinopathies: a tale of two proteins," *Annals of Neurology*, (3),**59**(2006)449-458.
- Goedert M. (2004) Tau protein and neurodegeneration, pp. 45-49, Elsevier.
- Gonzalez G.A. and Montminy M.R., "Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133," *Cell*, (4),**59**(1989)675-680.
- Greig N.H., Lahiri D.K. and Sambamurti K., "Butyrylcholinesterase: an important new target in Alzheimer's disease therapy," *International Psychogeriatrics*, (S1),**14**(2002)77-91.
- Greig N.H., Utsuki T., Yu Q.-s., Zhu X., Holloway H.W., Perry T., Lee B., Ingram D.K. and Lahiri D.K., "A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase," *Current Medical Research and Opinion*, (3),**17**(2001)159-165.
- Gsell W., Conrad R., Hicketier M., Sofic E., Frölich L., Wichart I., Jellinger K., Moll G., Ransmayr G. and Beckmann H., "Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type," *Journal of Neurochemistry*, (3),**64**(1995)1216-1223.
- Gurjar A.S., Andrisano V., Simone A.D. and Velingkar V.S., "Design, synthesis, in silico and in vitro screening of 1, 2, 4-thiadiazole analogues as non-peptide inhibitors of beta-secretase," *Bioorganic Chemistry*, **57**(2014)90-98.
- Harada K., Nakato K., Yarimizu J., Yamazaki M., Morita M., Takahashi S., Aota M., Saita K., Doihara H. and Sato Y., "A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1, 2, 4-triazol-4-yl]-2, 1, 3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease," *European Journal of Pharmacology*, (1-3),**685**(2012)59-69.
- Hardy J.A. and Higgins G.A., "Alzheimer's disease: the amyloid cascade hypothesis," *Science*, (5054),**256**(1992)184-186.
- Harte N.P., Klyubin I., McCarthy E.K., Min S., Garrahy S.A., Xie Y., Davey G.P., Boland J.J., Rowan M.J. and Mok K.H., "Amyloid oligomers and mature fibrils prepared from an innocuous protein cause diverging cellular death mechanisms," *Journal of Biological Chemistry*, 2015)jbc. M115. 676072.
- Heemels M.-T., "Neurodegenerative diseases," *Nature*, (7628),**539**(2016)179-180.
- Iadecola C., "Neurovascular regulation in the normal brain and in Alzheimer's disease," *Nature Reviews Neuroscience*, (5),**5**(2004)347-360.

- Higuchi M. (2014) Antioxidant Properties of Wheat Bran against Oxidative Stress. *Wheat and Rice in Disease Prevention and Health*, pp. 181-199, Elsevier.
- Hoang S., Nhan K C., and Edward H K., "The multifaceted nature of amyloid precursor protein and its proteolytic fragments : friends and foes, " *Acta Neuropathol.* **129** (2015) 1-19.
- Higuchi M. (2014) Antioxidant Properties of Wheat Bran against Oxidative Stress. *Wheat and Rice in Disease Prevention and Health*, pp. 181-199, Elsevier.
- Inestrosa N.C., Alvarez A., Perez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C. and Garrido J., "Acetylcholinesterase accelerates assembly of amyloid- β -peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme," *Neuron*, (4),**16**(1996)881-891. Jagust W.J. and Mormino E.C., "Lifespan brain activity, β -amyloid, and Alzheimer's disease," *Trends in cognitive sciences*, (11),**15**(2011)520-526.
- Jin-Shuai Lan R.-F.Z., Xiao-Yi Jiang, Jian-wei Hou, Yun Liu, Zheng-Hao Hu, Hong-Xin Li, Yin Li, Sai-Sai Xie, Yue Ding, Tong Zhang, "Design, synthesis and evaluation of novel ferulic acid derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease," *Bioorganic Chemistry*, **94**(2020)103413.
- Jung J.-S., Yan J.-J., Li H.-M., Sultan M.T., Yu J., Lee H.-S., Shin K.-J. and Song D.-K., "Protective effects of a dimeric derivative of ferulic acid in animal models of Alzheimer's disease," *European Journal of Pharmacology*, **782**(2016)30-34.
- Kageyama K., Hanada K., Moriyama T., Imaizumi T., Satoh K. and Suda T., "Differential regulation of CREB and ERK phosphorylation through corticotropin-releasing factor receptors type 1 and 2 in AtT-20 and A7r5 cells," *Molecular and Cellular Endocrinology*, (1-2),**263**(2007)90-102.
- Kamal A., Shaik A.B., Reddy G.N., Kumar C.G., Joseph J., Kumar G.B., Purushotham U. and Sastry G.N., "Synthesis, biological evaluation, and molecular modeling of (E)-2-aryl-5-styryl-1, 3, 4-oxadiazole derivatives as acetylcholine esterase inhibitors," *Medicinal Chemistry Research*, (4),**23**(2014)2080-2092.
- Klinkenberg I. and Blokland A., "The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies," *Neuroscience & Biobehavioral Reviews*, (8),**34**(2010)1307-1350.
- Kono Y., "Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase," *Archives of Biochemistry and Biophysics*, (1),**186**(1978)189-195.
- Kumar D., Gupta S.K., Ganeshpurkar A., Gutti G., Krishnamurthy S., Modi G. and Singh S.K., "Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease," *European Journal of Medicinal Chemistry*, **150**(2018a)87-101.
- Kumar J., Gill A., Shaikh M., Singh A., Shandilya A., Jameel E., Sharma N., Mrinal N., Hoda N. and Jayaram B., "Pyrimidine-Triazolopyrimidine and Pyrimidine-Pyridine Hybrids as Potential Acetylcholinesterase Inhibitors for Alzheimer's Disease," *ChemistrySelect*, (2),**3**(2018b)736-747.

- Kumar M., Sharma P., Maheshwari R., Tekade M., Shrivastava S.K. and Tekade R.K. (2018c) Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors, pp. 397-437, Elsevier.
- Lalonde R., "The neurobiological basis of spontaneous alternation," *Neuroscience & Biobehavioral Reviews*, (1),**26**(2002)91-104.
- Lemkul J.A. and Bevan D.R., "The role of molecular simulations in the development of inhibitors of amyloid β -peptide aggregation for the treatment of Alzheimer's disease," *ACS Chemical Neuroscience*, (11),**3**(2012)845-856.
- Li T., Pan W., Wang K., Liu W., Ma Q. and Sang Z., "Novel Ferulic Acid-donepezil Hybrids as Multifunctional Agents for the Treatment of Alzheimer's Disease with Butyrylcholinesterase, Amyloid- β , Antioxidant and Neuroprotective Properties," *Letters in Drug Design & Discovery*, (8),**14**(2017)918-929.
- Lineweaver H. and Burk D., "The determination of enzyme dissociation constants," *Journal of the American Chemical Society*, (3),**56**(1934)658-666.
- Lisa Prostack, Efrat Barnea, and P.Y. and Zharhary D. BACE1 Activity Assay Kit (Fluorescent). Sigma–Aldrich, S.L., USA. (ed), Sigma–Aldrich, St. Louis, USA.
- López-Iglesias B., Pérez C.n., Morales-García J.A., Alonso-Gil S., Pérez-Castillo A., Romero A., López M.G., Villarroya M., Conde S. and Rodríguez-Franco M.I., "New melatonin–n, n-dibenzyl (n-methyl) amine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease," *Journal of Medicinal Chemistry*, (9),**57**(2014)3773-3785.
- Lowry O.H., Rosebrough N.J., Farr A.L. and Randall R.J., "Protein measurement with the Folin phenol reagent," *Journal of Biological Chemistry*, (1),**193**(1951)265-275.
- Lu C., Guo Y., Yan J., Luo Z., Luo H.-B., Yan M., Huang L. and Li X., "Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease," *Journal of Medicinal Chemistry*, (14),**56**(2013)5843-5859.
- Maccioni R.B., Farías G., Morales I. and Navarrete L., "The revitalized tau hypothesis on Alzheimer's disease," *Archives of Medical Research*, (3),**41**(2010)226-231.
- Malamas M.S., Barnes K., Hui Y., Johnson M., Lovering F., Condon J., Fobare W., Solvibile W., Turner J. and Hu Y., "Novel pyrrolyl 2-aminopyridines as potent and selective human β -secretase (BACE1) inhibitors," *Bioorganic & Medicinal Chemistry Letters*, (7),**20**(2010)2068-2073.
- Manetti D., Ghelardini C., Bartolini A., Dei S., Galeotti N., Gualtieri F., Romanelli M.N. and Teodori E., "Molecular simplification of 1, 4-diazabicyclo [4.3. 0] nonan-9-ones gives piperazine derivatives that maintain high nootropic activity," *Journal of Medicinal Chemistry*, (23),**43**(2000)4499-4507.
- Mannhold R. (2012) Method and principle of medicinal chemistry, pp. 03-54, Willy-VCH.

- Marco-Contelles J., do Carmo Carreiras M., Rodríguez C., Villarroya M. and García A.G., "Synthesis and pharmacology of galantamine," *Chemical Reviews*, (1),**106**(2006)116-133.
- Mayr B. and Montminy M., "Transcriptional regulation by the phosphorylation-dependent factor CREB," *Nature Reviews: Molecular Cell Biology*, (8),**2**(2001)599.
- McCord J.M. and Fridovich I., "Superoxide dismutase an enzymic function for erythrocuprein (hemocuprein)," *Journal of Biological Chemistry*, (22),**244**(1969)6049-6055.
- Meena P., Nemaish V., Khatri M., Manral A., Luthra P.M. and Tiwari M., "Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease," *Bioorganic & Medicinal Chemistry*, (5),**23**(2015)1135-1148.
- Mei W.-w., Ji S.-s., Xiao W., Wang X.-d., Jiang C.-s., Ma W.-q., Zhang H.-y., Gong J.-x. and Guo Y.-w., "Synthesis and biological evaluation of benzothiazol-based 1, 3, 4-oxadiazole derivatives as amyloid β -targeted compounds against Alzheimer's disease," *Monatshefte für Chemie-Chemical Monthly*, (10),**148**(2017)1807-1815.
- Mezeiova E., Spilovska K., Nepovimova E., Gorecki L., Soukup O., Dolezal R., Malinak D., Janockova J., Jun D. and Kuca K., "Profiling donepezil template into multipotent hybrids with antioxidant properties," *Journal of Enzyme Inhibition and Medicinal Chemistry*, (1),**33**(2018)583-606.
- Michaelson D.M., "APOE ϵ 4: The most prevalent yet understudied risk factor for Alzheimer's disease," *Alzheimer's & Dementia*, (6),**10**(2014)861-868.
- Mishra P., Sharma P., Tripathi P.N., Gupta S.K., Srivastava P., Seth A., Tripathi A., Krishnamurthy S. and Shrivastava S.K., "Design and Development of 1, 3, 4-Oxadiazole Derivatives as Potential Inhibitors of Acetylcholinesterase to Ameliorate Scopolamine-Induced Cognitive Dysfunctions," *Bioorganic Chemistry*, **89**(2019a)103025.
- Mishra P., Sharma P., Tripathi P.N., Gupta S.K., Srivastava P., Seth A., Tripathi A., Krishnamurthy S. and Shrivastava S.K., "Design and Development of 1, 3, 4-Oxadiazole Derivatives as Potential Inhibitors of Acetylcholinesterase to Ameliorate Scopolamine-Induced Cognitive Dysfunctions," *Bioorganic Chemistry*, 2019b)103025.
- Mittler R., "Oxidative stress, antioxidants and stress tolerance," *Trends in Plant Science*, (9),**7**(2002)405-410.
- Mobius H.J., Stoffler A. and Graham S.M., "Memantine hydrochloride: pharmacological and clinical profile," *Drugs of Today*, (8),**40**(2004)685-696.
- Moore A.N., Waxham M.N. and Dash P.K., "Neuronal activity increases the phosphorylation of the transcription factor cAMP response element-binding protein (CREB) in rat hippocampus and cortex," *Journal of Biological Chemistry*, (24),**271**(1996)14214-14220.

- More S.S. and Vince R., "Potential of a γ -glutamyl-transpeptidase-stable glutathione analogue against amyloid- β toxicity," *ACS Chemical Neuroscience*, (3),**3**(2012)204-210.
- Morris R., "Developments of a water-maze procedure for studying spatial learning in the rat," *Journal of Neuroscience Methods*, (1),**11**(1984)47-60.
- Musad E.A., Mohamed R., Saeed B.A., Vishwanath B.S. and Rai K.L., "Synthesis and evaluation of antioxidant and antibacterial activities of new substituted bis (1, 3, 4-oxadiazoles), 3, 5-bis (substituted) pyrazoles and isoxazoles," *Bioorganic & Medicinal Chemistry Letters*, (12),**21**(2011)3536-3540.
- Nabavi S.F., Devi K.P., Malar D.S., Sureda A., Daglia M. and Nabavi S.M., "Ferulic acid and Alzheimer's disease: promises and pitfalls," *Mini Reviews in Medicinal Chemistry*, (9),**15**(2015)776-788.
- Naslund J., Jensen M., Tjernberg L.O., Thyberg J., Terenius L. and Nordstedt C., "The metabolic pathway generating p3, an A β -peptide fragment, is probably non-amyloidogenic," *Biochemical and Biophysical Research Communications*, (2),**204**(1994)780-787.
- Ohkawa H., Ohishi N. and Yagi K., "Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction," *Analytical Biochemistry*, (2),**95**(1979)351-358.
- Olney J.W., Wozniak D.F. and Farber N.B., "Excitotoxic neurodegeneration in Alzheimer disease: new hypothesis and new therapeutic strategies," *Archives of Neurology*, (10),**54**(1997)1234-1240.
- Onishi T., Iwashita H., Uno Y., Kunitomo J., Saitoh M., Kimura E., Fujita H., Uchiyama N., Kori M. and Takizawa M., "A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)-methylsulfinyl] phenyl}-1-benzofuran-5-yl)-1, 3, 4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease," *Journal of Neurochemistry*, (6),**119**(2011)1330-1340.
- Önkol T., Gökçe M., Orhan İ. and Kaynak F., "Design, synthesis and evaluation of some novel 3 (2H)-pyridazinone-2-yl acetohydrazides as acetylcholinesterase and butyrylcholinesterase inhibitors," *Organic Communications*, (1),**6**(2013).
- Özkay Ü.D., Can Ö.D., Sağlık B.N., Çevik U.A., Levent S., Özkay Y., Iğın S. and Atlı Ö., "Design, synthesis, and AChE inhibitory activity of new benzothiazole-piperazines," *Bioorganic & Medicinal Chemistry Letters*, (22),**26**(2016)5387-5394.
- Patani G.A. and LaVoie E.J., "Bioisosterism: a rational approach in drug design," *Chemical Reviews*, (8),**96**(1996)3147-3176.
- Peauger L., Azzouz R., Gembus V., Tintas M.-L., Sopková-de Oliveira Santos J., Bohn P., Papamicaël C. and Levacher V., "Donepezil-based central acetylcholinesterase inhibitors by means of a "bio-oxidizable" prodrug strategy: design, synthesis, and in vitro biological evaluation," *Journal of Medicinal Chemistry*, (13),**60**(2017a)5909-5926.

- Peauger L., Azzouz R., Gembus V., Tintas M.-L., Sopková-de Oliveira Santos J., Bohn P., Papamicaël C. and Levacher V., "Donepezil-based central acetylcholinesterase inhibitors by means of a "bio-oxidizable" prodrug strategy: design, synthesis, and in vitro biological evaluation," *Journal of Medicinal Chemistry*, (13),**60**(2017b)5909-5926.
- Perry E.K., "The cholinergic hypothesis—ten years on," *British Medical Bulletin*, (1),**42**(1986)63-69.
- Pi R., Mao X., Chao X., Cheng Z., Liu M., Duan X., Ye M., Chen X., Mei Z. and Liu P., "Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid- β -mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo," *PloS One*, (2),**7**(2012).
- Placer Z.A., Cushman L.L. and Johnson B.C., "Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems," *Analytical Biochemistry*, (2),**16**(1966)359-364.
- Plaschke K., Ranneberg T., Bauer J., Weigand M., Hoyer S. and Bardenheuer H.J., "The effect of stepwise cerebral hypoperfusion on energy metabolism and amyloid precursor protein (APP) in cerebral cortex and hippocampus in the adult rat," *Annals of the New York Academy of Sciences*, **826**(1997)502-506.
- Polinsky R.J., "Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease," *Clinical Therapeutics*, (4),**20**(1998)634-647.
- Pugazhenth S., Wang M., Pham S., Sze C.-I. and Eckman C.B., "Downregulation of CREB expression in Alzheimer's brain and in A β -treated rat hippocampal neurons," *Molecular Neurodegeneration*, (1),**6**(2011)60.
- Ramirez-Bermudez J., "Alzheimer's disease: critical notes on the history of a medical concept," *Archives of Medical Research*, (8),**43**(2012)595-599.
- Ransohoff R.M., "How neuroinflammation contributes to neurodegeneration," *Science*, (6301),**353**(2016)777-783.
- Ravi R., and Reddy P., "Amyloid Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons," *J Alzheimers Dis.* **57** (2017) 975–999.
- Reddy P.H., "Mitochondrial medicine for aging and neurodegenerative diseases," *Neuromolecular Medicine*, (4),**10**(2008)291-315.
- Rehman A.-u., Nafeesa K., Abbasi M.A., Siddiqui S.Z., Rasool S., Shah S.A.A. and Ashraf M., "Synthesis of new heterocyclic 3-piperidinyl-1, 3, 4-oxadiazole derivatives as potential drug candidate for the treatment of Alzheimer's disease," *Cogent Chemistry*, (1),**4**(2018)1472197.
- Rehman A., Fatima A., Abbas N., Abbasi M., Khan K., Ashraf M., Ahmad I. and Ejaz S., "Synthesis, characterization and biological screening of 5-substituted-1, 3, 4-oxadiazole-2yl-N-(2-methoxy-5-chlorophenyl)-2-sulfanyl acetamide," *Pak. J. Pharm. Sci*, (2),**26**(2013)345-352.

- Rosini M., Simoni E., Caporaso R., Basagni F., Catanzaro M., Abu I.F., Fagiani F., Fusco F., Masuzzo S. and Albani D., "Merging memantine and ferulic acid to probe connections between NMDA receptors, oxidative stress and amyloid- β peptide in Alzheimer's disease," *European Journal of Medicinal Chemistry*, **180**(2019)111-120.
- Ryu J., Kanapathipillai M., Lentzen G. and Park C.B., "Inhibition of β -amyloid peptide aggregation and neurotoxicity by α -D-mannosylglycerate, a natural extremolyte," *Peptides*, (4),**29**(2008)578-584.
- Sadigh-Eteghad S., Sabermarouf B., Majdi A., Talebi M., Farhoudi M. and Mahmoudi J., "Amyloid-beta: a crucial factor in Alzheimer's disease," *Medical Principles and Practice*, (1),**24**(2015)1-10.
- Saeedi M., Mohtadi-Haghighi D., Mirfazli S.S., Mahdavi M., Hariri R., Lotfian H., Edraki N., Iraj A., Firuzi O. and Akbarzadeh T., "Design and Synthesis of Selective Acetylcholinesterase Inhibitors: Arylisoxazole-Phenylpiperazine Derivatives," *Chemistry & Biodiversity*, (2),**16**(2019)e1800433.
- Saitoh M., Kunitomo J., Kimura E., Hayase Y., Kobayashi H., Uchiyama N., Kawamoto T., Tanaka T., Mol C.D., Dougan D.R., Textor G.S., Snell G.P. and Itoh F., "Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3 β ," *Bioorganic and Medicinal Chemistry*, (5),**17**(2009)2017-2029.
- Sang Z., Pan W., Wang K., Ma Q., Yu L., Yang Y., Bai P., Leng C., Xu Q. and Li X., "Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease," *European Journal of Medicinal Chemistry*, **130**(2017)379-392.
- Sang Z., Wang K., Han X., Cao M., Tan Z. and Liu W., "Design, synthesis, and evaluation of novel ferulic acid derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease," *ACS Chemical Neuroscience*, (2),**10**(2018)1008-1024.
- Sarter M., Bruno J. and Dudchenko P., "Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification," *Psychopharmacology*, (1),**101**(1990)1-17.
- Saura C.A. and Valero J., "The role of CREB signaling in Alzheimer's disease and other cognitive disorders," *Reviews in the Neurosciences*, (2),**22**(2011)153-169.
- Seth A., Sharma P.A., Tripathi A., Choubey P.K., Srivastava P., Tripathi P.N. and Shrivastava S.K., "Design, synthesis, evaluation and molecular modeling studies of some novel N-substituted piperidine-3-carboxylic acid derivatives as potential anticonvulsants," *Medicinal Chemistry Research*, (4),**27**(2018)1206-1225.
- Sgarbossa A., Giacomazza D. and Di Carlo M., "Ferulic acid: a hope for Alzheimer's disease therapy from plants," *Nutrients*, (7),**7**(2015)5764-5782.
- Sharma P., Srivastava P., Seth A., Tripathi P.N., Banerjee A.G. and Shrivastava S.K., "Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's

- disease and potential therapeutic strategies," *Progress in Neurobiology*, **174**(2019a)53-89.
- Sharma P., Tripathi A., Tripathi P.N., Prajapati S.K., Seth A., Tripathi M.K., Srivastava P., Tiwari V., Krishnamurthy S. and Shrivastava S.K., "Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease," *European Journal of Medicinal Chemistry*, **167**(2019b)510-524.
- Sharma P., Tripathi A., Tripathi P.N., Singh S.S., Singh S.P. and Shrivastava S.K., "Novel Molecular Hybrids of N-Benzylpiperidine and 1, 3, 4-Oxadiazole as Multitargeted Therapeutics to Treat Alzheimer's Disease," *ACS Chemical Neuroscience*, **10**(2019c)4361-4384.
- Shidore M., Machhi J., Shingala K., Murumkar P., Sharma M.K., Agrawal N., Tripathi A., Parikh Z., Pillai P. and Yadav M.R., "Benzylpiperidine-linked diarylthiazoles as potential anti-Alzheimer's agents: synthesis and biological evaluation," *Journal of Medicinal Chemistry*, (12),**59**(2016)5823-5846.
- Shrivastava S.K., Sinha S.K., Srivastava P., Tripathi P.N., Sharma P., Tripathi M.K., Tripathi A., Choubey P.K., Waiker D.K. and Aggarwal L.M., "Design and development of novel p-aminobenzoic acid derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease," *Bioorganic Chemistry*, **82**(2019)211-223.
- Sies H. (2000) Oxidative stress and vascular disease, pp. 1-8, Springer.
- Silva D., Chioua M., Samadi A., Agostinho P., Garção P., Lajarín-Cuesta R., de los Ríos C., Iriepa I., Moraleta I. and Gonzalez-Lafuente L., "Synthesis, Pharmacological Assessment, and Molecular Modeling of Acetylcholinesterase/Butyrylcholinesterase Inhibitors: Effect Against Amyloid- β -Induced Neurotoxicity," *ACS Chemical Neuroscience*, (4),**4**(2013)547-565.
- Singh R. and Bansal R., "Investigations on 16-arylideno steroids as a new class of neuroprotective agents for the treatment of Alzheimer's and Parkinson's diseases," *ACS Chemical Neuroscience*, (1),**8**(2017)186-200.
- Small S.A., Perera G.M., DeLaPaz R., Mayeux R. and Stern Y., "Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease," *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*, (4),**45**(1999)466-472.
- Smith M.A., Rottkamp C.A., Nunomura A., Raina A.K. and Perry G., "Oxidative stress in Alzheimer's disease," *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, (1),**1502**(2000)139-144.
- Sosa-Ortiz A.L., Acosta-Castillo I. and Prince M.J., "Epidemiology of dementias and Alzheimer's disease," *Archives of Medical Research*, (8),**43**(2012)600-608.
- Sprung M.A., "A Summary of the Reactions of Aldehydes with Amines," *Chemical Reviews*, (3),**26**(1940)297-338.

- Tripathi A., Choubey P.K., Sharma P., Seth A., Tripathi P.N., Tripathi M.K., Prajapati S.K., Krishnamurthy S. and Shrivastava S.K., "Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1, 3, 4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease," *European Journal of Medicinal Chemistry*, **183**(2019a)111707.
- Tripathi P.N., Srivastava P., Sharma P., Seth A. and Shrivastava S.K., "Design and development of novel N-(pyrimidin-2-yl)-1, 3, 4-oxadiazole hybrids to treat cognitive dysfunctions," *Bioorganic & Medicinal Chemistry*, (7),**27**(2019b)1327-1340.
- Tripathi P.N., Srivastava P., Sharma P., Tripathi M.K., Seth A., Tripathi A., Rai S.N., Singh S.P. and Shrivastava S.K., "Biphenyl-3-oxo-1, 2, 4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory," *Bioorganic Chemistry*, **85**(2019c)82-96.
- Umar T., Shalini S., Raza M.K., Gusain S., Kumar J., Seth P., Tiwari M. and Hoda N., "A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo [3, 4-b] pyridine derivatives against Alzheimer's disease," *European Journal of Medicinal Chemistry*, **175**(2019)2-19.
- Viegas-Junior C., Danuello A., da Silva Bolzani V., Barreiro E.J. and Fraga C.A.M., "Molecular hybridization: a useful tool in the design of new drug prototypes," *Current Medicinal Chemistry*, (17),**14**(2007)1829-1852.
- von Gunten A., Pocnet C. and Rossier J., "The impact of personality characteristics on the clinical expression in neurodegenerative disorders—a review," *Brain Research Bulletin*, (4-5),**80**(2009)179-191.
- Wang Z., Wang Y., Wang B., Li W., Huang L. and Li X., "Design, synthesis, and evaluation of orally available clioquinol-moracin M hybrids as multitarget-directed ligands for cognitive improvement in a rat model of neurodegeneration in Alzheimer's disease," *Journal of Medicinal Chemistry*, (21),**58**(2015)8616-8637.
- WHO (2015) 2015 Alzheimer's disease facts and figures, pp. 332-384.
- Wilkinson D.G., "The pharmacology of donepezil: a new treatment for Alzheimer's disease," *Expert Opinion on Pharmacotherapy*, (1),**1**(1999)121-135.
- Willis A., Mihalevich M., Neff R. and Mendelowitz D., "Three types of postsynaptic glutamatergic receptors are activated in DMNX neurons upon stimulation of NTS," *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, (6),**271**(1996)R1614-R1619.
- Wolf A., Bauer B., Abner E.L., Ashkenazy-Frolinger T. and Hartz A.M., "A comprehensive behavioral test battery to assess learning and memory in 129S6/Tg2576 mice," *PloS One*, (1),**11**(2016)e0147733.
- Wyss-Coray T. and Mucke L., "Inflammation in neurodegenerative disease—a double-edged sword," *Neuron*, (3),**35**(2002)419-432.

- Xu Y., Zhang J., Wang H., Mao F., Bao K., Liu W., Zhu J., Li X., Zhang H. and Li J., "Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer's Disease Agents," *ACS Chemical Neuroscience*, 2018)DOI: 10.1021/acscchemneuro.1028b00357.
- Yan R. and Vassar R., "Targeting the β secretase BACE1 for Alzheimer's disease therapy," *The Lancet Neurology*, (3),**13**(2014)319-329.
- Yates S.L., Burgess L.H., Kocsis-Angle J., Antal J.M., Dority M.D., Embury P.B., Piotrkowski A.M. and Brunden K.R., "Amyloid β and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia," *Journal of Neurochemistry*, (3),**74**(2000)1017-1025.
- Zha X., Lamba D., Zhang L., Lou Y., Xu C., Kang D., Chen L., Xu Y., Zhang L. and De Simone A., "Novel tacrine–benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer's disease: design, synthesis, biological evaluation, and X-ray crystallography," *Journal of Medicinal Chemistry*, (1),**59**(2015)114-131.
- Zhang X., Breslav M., Grimm J., Guan K., Huang A., Liu F., Maryanoff C.A., Palmer D., Patel M. and Qian Y., "A new procedure for preparation of carboxylic acid hydrazides," *The Journal of organic chemistry*, (26),**67**(2002)9471-9474.
- Zhou W., Zhong G., Rao X., Xie H., Zeng S., Chi T., Zou L., Wu D. and Hu W., "Identification of aminopyridazine-derived antineuroinflammatory agents effective in an Alzheimer's mouse model," *ACS Medicinal Chemistry Letters*, (11),**3**(2012)903-907.
- Zhu X., Su B., Wang X., Smith M. and Perry G., "Causes of oxidative stress in Alzheimer disease," *Cellular and Molecular Life Sciences*, (17),**64**(2007)2202-2210.
- Zhu Z., Yang T., Zhang L., Liu L., Yin E., Zhang C., Guo Z., Xu C. and Wang X., "Inhibiting A β toxicity in Alzheimer's disease by a pyridine amine derivative," *European Journal of Medicinal Chemistry*, **168**(2019)330-339.